Clinical trial Recruiting at 1 site Observational Ages 0 Days to 17

DNA sequencing of patient and family samples to help diagnose rare genetic diseases

Official title: Sequenziamento Esomico e Genomico di Campioni di DNA, Come Richiesto Sia da Specifici Progetti di Ricerca Che Dalle Necessita' Diagnostiche Dell'Istituto Gaslini, da Effettuarsi Nell'Ambito Del Cosiddetto ''Joint,Lab,Genomico'' Istituito Tra IGG e IIT / Exome and Genome Sequencing of DNA Samples, as Required by Specific Research Projects and the Diagnostic Needs of the Gaslini Institute, to Be Performed Within the Framework of the "Joint Genomic Lab" Established Between IGG and IIT

Run by Istituto Giannina Gaslini · NCT07877688 · Data updated 2026-11-12

We’re testing whether whole-exome or whole-genome sequencing of patients and their parents can help diagnose rare genetic diseases when other findings are not yet clear.

More Rare Genetic Disease trials

Quick facts

Study typeObservational
Ages0 Days to 17 Years
SexAll
Enrollment1950 (estimated)
SponsorIstituto Giannina Gaslini
Academic / other
Locations1 site (Genova)
StatusRecruiting
StartedOctober 11, 2021
Main results expectedDecember 31, 2026
Study endsDecember 31, 2026
Registry record updatedOctober 16, 2026
Trial IDNCT07877688 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are patients with rare genetic diseases lacking a clinical or molecular diagnosis, whose clinicians deem a genetic etiology likely and who (and their family) consent to WES/WGS and data use.

Probably not a fit

Patients who already have a confirmed diagnosis or who do not consent to sequencing or data sharing may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational, translational cohort study conducted at two centers, with one center recruiting patients. DNA from patients and their parents will be collected and stored, then sent to a partner institution for sequencing. Informed consent is required, and only cases with suspected genetic etiologies and no established diagnosis are eligible. The project is funded by the participating centers and uses existing biobank resources to support sequencing and data use. Overall, the study aims to explore how sequencing can support diagnostic efforts in rare genetic diseases.

Why it matters

Potential benefit: If successful, sequencing could provide a genetic diagnosis for patients who currently lack one, guiding management and counseling.

How similar studies have gone: Similar sequencing-based diagnostic approaches have shown diagnostic yield in some rare diseases, though results vary by condition and cohort.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients affected by a rare genetic disease.
* Patients for whom a clinical and/or molecular diagnosis has not yet been established.
* The referring IGG clinician considers the clinical phenotype worthy of further investigation and suggestive of a genetic etiology.
* The family consents to participate in the study, together with the affected individual, including undergoing WES and/or WGS and authorizing the use of the resulting data.

Exclusion Criteria:

* Failure to meet at least one of the inclusion criteria listed above.
* Previous whole-genome sequencing (WGS).

Where it's running

  • IRCCS Istituto Giannina Gaslini
    Genova, Italy
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.